XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Stock Based Compensation
 3 Months Ended
Mar. 31, 2022
Share-based Payment Arrangement [Abstract]  
Stock Based Compensation Stock-Based CompensationThe following table summarizes the stock-based compensation expense recognized under all of the Company’s stock plans for the three months ended March 31, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):
Three Months Ended
March 31,
20222021
Stock options$780 $589 
Restricted stock2,275 757 
Total stock-based compensation expense$3,055 $1,346 
Unrecognized compensation expense related to total share-based payments outstanding as of March 31, 2022, was $21.6 million.
Options
The Company’s outstanding stock options consisted of the following:
Shares
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Contractual
Term
(Years)
Aggregate
Intrinsic
Value
(in millions)
Options outstanding at January 1, 2022813,965 $22.74 3.20$41.6 
Options granted
75,271 55.07 — — 
Options exercised
(38,500)17.37 — 0.9 
Options forfeited
— — — — 
Options outstanding at March 31, 2022850,736 $25.84 2.94$22.8 
Options exercisable at March 31, 2022591,725 $9.33 1.79$20.7 
During the three months ended March 31, 2022, options were exercised for 38,500 shares of the Company’s common stock, resulting in proceeds of $0.7 million. During the three months ended March 31, 2021, no stock options were exercised.
During the three months ended March 31, 2022, the Company granted 75,271 stock options to certain ApolloMed employees and Board members. The options granted during the three months ended March 31, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows:
March 31, 2022
Expected term
2.00 years - 2.25 years
Expected volatility
71.47% - 75.15%
Risk-free interest rate
1.02% - 1.06%
Market value of common stock
$20.23 - $22.73
Annual dividend yield
0 %
Forfeiture rate
0 %
Restricted Stock
The Company grants restricted stock to officers and employees which are earned based on service conditions. The grant date fair value of the restricted stock is that day’s closing market price of the Company’s common stock. During the three months ended March 31, 2022, the Company granted restricted stock totaling 76,828 shares, including 49,124 restricted stock with performance conditions, with a weighted average grant date fair value of $50.76. Restricted stock with performance conditions are recognized to the extent the performance conditions are probable of being achieved. The grant date fair value of restricted stock and restricted stock with performance conditions that are probable of being achieved were $3.9 million and will be recognized on a straight-line basis over the awards’ vesting period.
Warrants
The Company’s outstanding warrants consisted of the following:
Shares
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Contractual
Term
(Years)
Aggregate
Intrinsic
Value
(in millions)
Warrants outstanding at January 1, 20221,001,740 10.49 0.9463.1 
Warrants granted— — — — 
Warrants exercised(86,235)10.49 — 3.6 
Warrants expired/forfeited— — — — 
Warrants outstanding at March 31, 2022915,505 $10.49 0.69$34.8 

Exercise Price Per Share
Warrants
Outstanding
Weighted
Average
Remaining
Contractual Life
Warrants
Exercisable
Weighted
Average
Exercise Price
Per Share
$10.00 470,8270.69470,827 $10.00 
11.00 444,6780.69444,678 $11.00 
$ 10.00 – 11.00
915,505 0.69915,505 $10.49 
During the three months ended March 31, 2022 and 2021, common stock warrants were exercised for 86,235 and 421,002 shares of the Company’s common stock, respectively, which resulted in proceeds of approximately $0.9 million and $4.3 million, respectively. The exercise price ranged from $10.00 to $11.00 per share for the exercises during the three months ended March 31, 2022, and $9.00 to $11.00 per share for the exercises during the three months ended March 31, 2021, respectively.